Bladder Cancer VL

Exploring Tumor Biomarkers in Urothelial Carcinoma: Insights and Advancements in Bladder Cancer Research - Chad Ritch

Details
Sam Chang is joined by Chad Ritch for a discussion on tumor biomarkers and urothelial carcinoma. They discuss various types of biomarkers, including tissue-based and liquid-based markers. In the context of non-invasive bladder cancer, they mention the use of cytology as the standard despite its limitations in sensitivity. They also highlight the potential of RNA-based urinary biomarkers, such as C...

Optimizing Care of Bladder Cancer in Women - Katie Murray

Details
Katie Murray joins Ashish Kamat discusses optimizing care for bladder cancer in women. Dr. Murray highlights the need to understand the biologic and diagnostic differences, as well as the timing of diagnoses and survival disparities in bladder cancer among women. She emphasizes the importance of raising awareness among primary care physicians and advocating for early diagnosis, as women often expe...

Assessing the Effectiveness of N-803 for BCG Unresponsive Bladder Cancer: Promising Complete Remission Rates and Improved Long-Term Response - Patrick Soon-Shiong

Details
Sam Chang is joined by Patrick Soon-Shiong for a discussion on the effectiveness of N-803 for BCG unresponsive bladder cancer. They discussed the importance of an ideal profile for such an agent, which includes complete remission rate, durability of the response, and high cystectomy avoidance rate. They also highlighted the importance of the agent's safety and tolerability for urologists. The N-80...

Combining CG0070 Adenovirus Vector with Immune Checkpoint Blockade: Promising Results for BCG Unresponsive Bladder Cancer Patients - Roger Li

Details
Roger Li joins Ashish Kamat to discuss the CG0070 adenovirus vector and its potential use in combination with immune checkpoint blockade for patients with BCG unresponsive bladder cancer. The combination therapy has shown promising preliminary results, with 20 out of 22 patients achieving a complete response at three months and six out of eight patients maintaining a complete response at 12 months...

Targeting the HLA-E/NKG2A Axis to Overcome BCG Resistance in NMIBC, BCAN Translational Clinical Trial Award - Amir Horowitz

Details
Amir Horowitz joins Ashish Kamat to talk about his Bladder Cancer Translational Clinical Trial Award. An award given by the Bladder Cancer Advocacy Network (BCAN) aims to support early-phase patient-oriented research to transform bladder cancer care. The ENHANCE Trial is a phase II, single-arm trial starting with high-grade non-muscle-invasive bladder cancer (NMIBC) patients having received and fa...

The "Get Moving Trial" Home-based Pre and Rehabilitation Intervention for Muscle-invasive Bladder Cancer, BCAN Translational Clinical Trial Award - Sarah Psutka

Details
Sarah Psutka talks with Ashish Kamat about her Bladder Cancer Translational Clinical Trial Award. An award given by the Bladder Cancer Advocacy Network (BCAN) aims to support early-phase patient-oriented research to transform bladder cancer care. The "Get Moving Trial" is a phase I/II trial of a home-based pre and rehabilitation intervention for muscle-invasive bladder cancer with the use of an ap...

Developing Centers of Excellence for Treatment of Major Urological Cancers in Australia - Manish Patel

Details
Manish Patel joins Sam Chang to discuss the development of centers of excellence for the treatment of major urological cancers, specifically focusing on radical cystectomy. He explains how the UK's centralization of radical cystectomy in 2002 led to significant improvements in care and better survival rates. In Australia, 50 centers were doing radical cystectomies, but 39 were doing less than four...

Gene Expression and Molecular Subtyping in GU Cancers Presentation - Ewan Gibb

Details
Ewan Gibb, a PhD scientist, discusses the Decipher Bladder clinical test, a molecular subtyping assay for bladder cancer that predicts the risk of upstaging, identifies high-risk neuroendocrine-like disease and determines the benefit from neoadjuvant chemotherapy. The test breaks a patient's tumor into one of five subtypes and recognizes luminal and non-luminal categories, with neuroendocrine bein...

The SunRISe-4 Trial: A Critical Look at Immunotherapy in Bladder Cancer - Sarah Psutka

Details
In a detailed discussion between Sam Chang and Sarah Psutka, they explore the SunRISe-4 trial, a phase II study investigating the combination of TAR-200 agent with cetrelimab in muscle invasive bladder cancer patients. The trial targets those who are due for radical cystectomy but cannot or refuse the toxic cisplatin-based neoadjuvant chemotherapy, the current standard of care. The study focuses o...

Fueling Wellness with Flavor for Cancer Patients: The Wellness Principles - Gary Deng

Details
Gary Deng discusses his book "The Wellness Principles" in a conversation with Alicia Morgans. The book, which Dr. Deng describes as a wellness guide rather than a cookbook, is aimed at improving the quality of life for cancer patients by encouraging healthy lifestyles. Dr. Deng argues against extreme diet plans, instead promoting balanced, quick-to-make, and delicious meals. In particular, he shar...